loading page

Mining Alzheimer's Interactomes, Macromolecular Complexes and Pathways for drug discovery
  • +10
  • Kalpana Panneerselvam,
  • Krishna Kumar Tiwari,
  • Luana Licata,
  • Simona Panni,
  • Sylvie Ricard-Blum,
  • Sucharitha Balu,
  • Susie Huget,
  • Juan Jose Medina Reyes,
  • Eliot Ragueneau,
  • Livia Perfetto,
  • Birgit Meldal,
  • Sandra Orchard,
  • Henning Hermjakob
Kalpana Panneerselvam
EMBL-EBI

Corresponding Author:kalpanap@ebi.ac.uk

Author Profile
Krishna Kumar Tiwari
EMBL-EBI
Author Profile
Luana Licata
University of Rome Tor Vergata Macro Area of Mathematical Physical and Natural Sciences
Author Profile
Simona Panni
University of Calabria Department of Biology Ecology and Earth Sciences
Author Profile
Sylvie Ricard-Blum
Universite Lyon 1 IUT Lyon 1
Author Profile
Sucharitha Balu
EMBL-EBI
Author Profile
Susie Huget
EMBL-EBI
Author Profile
Juan Jose Medina Reyes
EMBL-EBI
Author Profile
Eliot Ragueneau
EMBL-EBI
Author Profile
Livia Perfetto
University of Rome La Sapienza Faculty of Mathematical Physical and Natural Sciences
Author Profile
Birgit Meldal
Pfizer Institute for Pharmaceutical Materials Science
Author Profile
Sandra Orchard
EMBL-EBI
Author Profile
Henning Hermjakob
EMBL-EBI
Author Profile

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that leads to dementia. Many cases are diagnosed annually and there is no currently available cure. Understanding the underlying disease biology of AD through the study of molecular networks, particularly by mapping clinical variants to tissue-specific interactomes and regulatory macromolecular assemblies, offers a promising avenue to elucidate altered disease pathways. This, in turn, could provide valuable insights for drug discovery. In this study, we leverage our manually curated AD-specific dataset from the IMEx consortium, which provides detailed interaction data, including the relationship between interacting partners, detection in specific host tissues and cell lines, and the impact of variants on interaction outcomes. By integrating these data with information on protein complex composition taken from the Complex Portal, we have identified relevant macromolecular assemblies enriched in AD networks. Further pathway enrichment analysis is conducted using Reactome, enabling a comprehensive exploration of disease mechanisms and potential therapeutic targets.
21 Nov 2024Submitted to PROTEOMICS
10 Jan 2025Submission Checks Completed
10 Jan 2025Assigned to Editor
10 Jan 2025Review(s) Completed, Editorial Evaluation Pending
10 Jan 2025Reviewer(s) Assigned